Clinical research firm ICON's Q2 revenue rises 1.2%, beats analyst estimates

Icon

29/07/2026 21:55

Overview
Clinical research firm's Q2 revenue rose 1.2% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company reaffirmed 2026 full-year revenue and adjusted EPS guidance

Outlook
ICON reaffirms 2026 revenue guidance of $7.85 bln to $8.15 bln
Company maintains 2026 adjusted diluted EPS outlook of $10.00 to $11.00
Company says second-half performance may vary due to pass-through activity

Result Drivers
COST MANAGEMENT - Co said disciplined cost management offset anticipated operational headwinds, per CEO Barry Balfe
PASS-THROUGH ACTIVITY - Higher pass-through activity contributed to revenue and net bookings, according to CEO Barry Balfe
STRATEGIC WINS - Strong strategic wins and new customer acquisition supported book-to-bill ratio, per CEO Barry Balfe

Company press release: ID:nBw4yqPWja

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$2.06 bln
$2.006 bln (14 Analysts)
Q2 Adjusted EPS
Beat
$2.56
$2.51 (14 Analysts)
Q2 Net Income
 
$72.58 mln
 
Q2 Adjusted EBITDA
Beat
$327.2 mln
$322.40 mln (12 Analysts)
Q2 Operating Income
Miss
$137.83 mln
$270.46 mln (11 Analysts)
Q2 Pretax Profit
Miss
$92.20 mln
$228.64 mln (10 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ICON PLC is $188.00, about 4.3% above its July 28 closing price of $180.24
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads
July 28 - IQVIA Q2 revenue beats estimates; outlook raised
July 29 - Fortrea Q2 revenue beats expectations, outlook raised
July 27 - AstraZeneca Q2 revenue rises 6% on demand for its cancer therapies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)